Clinical Research Collaborative Networks
The OSU Center for Clinical and Translational Science (CCTS) is committed to strengthening relations within the translational community at Ohio State as well as colleagues at other CTSA institutions and research networks. We are a founding member of three clinical research collaborative networks offering OSU investigators access to multiple research sites, shared infrastructure, and operational efficiencies to improve the quality, speed and performance of your clinical research study.
For more information, request a service through our Computerized Research Record (CoRR).
Pragmatic Clinical Trials Network
Pragmatic Clinical Trials Network is a partnership between the Division of General Internal Medicine, the Clinical Trials Management Office, and the Center for Clinical and Translational Science at The Ohio State University.
The Division of General Internal Medicine (GIM), the Clinical Trials Management Office (CTMO), and the Center for Clinical and Translational Science (CCTS) have partnered to develop infrastructure and mechanisms for implementing clinical trials in the GIM primary care clinics.
Why should I consider implementing a clinical trial in the GIM Primary Care Clinics?
- The GIM Primary Care Clinical Network consists of 6 clinical sites and a home visit primary care program, geographically spread throughout the greater Columbus area
- GIM clinical providers collectively care for over 26,000 patients, a majority of whom have multiple chronic diseases
- Many network providers care for special populations, including pediatric, disabled, transition, and home-bound patients
- Each GIM clinical site has primary care providers and clinical researchers who have completed regulatory and ethical training in human subjects research
- The GIM clinical sites collaborate closely with the CTMO and CCTS through every stage of clinical trial evaluation, implementation, and recruitment
- The GIM clinical sites are a part of the Ohio Clinical Trials Collaborative (OCTC), a statewide network of primary care clinics that are prepared to conduct clinical trials that can work with researchers to disseminate their clinical trial to all of the clinics in the OCTC Network
How do I know if a trial is right for implementation in the GIM primary care clinics?
GIM primary care providers care for a vast array of conditions. Commonly managed chronic disease issues include, but are not limited to:
- Cardiovascular: Hypertension, Hyperlipidemia, Coronary Artery Disease, Congestive Heart Failure, and Anti-Coagulation Monitoring
- Pulmonary: Asthma, Chronic Obstructive Pulmonary Disease
- Gastrointestinal: Gastro-Esophageal Reflux Disease, Irritable Bowel Syndrome
- Renal: Chronic Kidney Disease
- Endocrine: Diabetes Mellitus, Hypothyroidism
- Psychiatric: Depression, Anxiety, Attention Deficit (Hyperactive) Disorder
- Genetic/ Developmental: Autism, Down Syndrome
- Other: Chronic Pain, Obesity, Tobacco Abuse
If you have a clinical trial that may be appropriate for the GIM Primary Care Clinical Network, please contact the following individuals:
Dr. Seuli Brill
Director, Pragmatic Clinical Trials Network
Research Director, Division of General Internal Medicine
Clinical Research Coordinator
Division of General Internal Medicine
Ohio Clinical Trials Network (OCTC)
Established in May 2013, the Ohio Clinical Trials Collaborative (OCTC) is a statewide model comprised of Ohio's three Clinical and Translational Science Awards (CTSA) - The Ohio State University Center for Clinical and Translational Science, Clinical and Translational Science Collaborative (CTSC) of Cleveland, and the University of Cincinnati Center for Clinical and Translational Science and Training - that initiated discussions to develop this clinical trials concept statewide.
In addition to the three CTSA sites, partners in the statewide network include: Cincinnati Children's Hospital Medical Center, Cleveland Clinic, MetroHealth Medical Center, Nationwide Children's Hospital, Practice Based Research Network, and University Hospitals Case Medical Center. In partnership with the State of Ohio, OCTC will contribute to the success of Governor Kasich's vision for a statewide Medical Corridor. Contact Kim Toussant with questions.
Midwest Area Research Consortium for Health (MARCH)
The Midwest Area Research Consortium for Health (MARCH) provides an established infrastructure for investigators and external sponsors who want to conduct collaborative clinical research at academic institutions across the Midwest. MARCH aims to promote collaboration opportunities to enhance ethnic diversity and demographic variety in clinical research, provide access to large sample size research across multiple sites, and increase opportunities to conduct research on rare diseases.
MARCH provides opportunities for improved efficiency through reciprocal IRB deferral agreements, accessibile clinical research management tools, enhanced participant recruitment via multi-site research studies, and simplified fiscal management. Contact Kim Toussant with questions.
Appalachian Translational Research Network (ATRN)
The Appalachian Translational Research Network (ATRN) is committed to addressing the significant health challenges and disparities specific to Appalachia by enhancing research collaborations to speed the translation of scientific discoveries to health improvements for this region.
The ATRN seeks to foster Community Engagement and Outreach to those in the Appalachian region. In addition, the ATRN will serve as a conduit for enhancing T1 research collaborations in areas relevant to the chronic health conditions prevalent in Appalachia.
Strategic Pharma-Academic Research Consortium for Translational Medicine (SPARC)
The Strategic Pharma-Academic Research Consortium for Translational Medicine (SPARC) is an organization designed to spark innovative collaborations across academic research centers and the biopharmaceutical industry. The program includes a list of inaugural members made up of four academic medical centers supported by the NIH Clinical and Translational Science Awards, as well as two major pharmaceutical companies, Eli Lilly and Co. and Takeda Pharmaceuticals International Inc.
SPARC was born in July 2012, when the Indiana Clinical and Translational Science Institute (CTSI) hosted a first-of-its-kind meeting to discuss potential partnerships among 17 directors of CTSA-funded centers, university technology transfer officers, and industry. The inaugural CTSA-funded institutions to join the consortium are: The Indiana Clinical and Translational Science Institute; The Ohio State University Center for Clinical and Translational Science; Northwestern University Clinical and Translational Sciences Institute; and The Institute of Clinical and Translational Sciences at Washington University in St. Louis.
The consortium will initially focus on advancing research on autoimmune diseases because of the high concentration of expertise on the topic among partnership members and the lack of other large-scale consortiums focused on the topic.